Search Results 51-60 of 16563 for ������������KA���:ZA31���24������ ���������������������������������

  1. Publications - Deirdre R. Pachman, M.D. - Mayo Clinic

    ... KA, Griffin JM, Chlan LL, Austin JD, Ridgeway JL ... 2016 Dec; 24 (12):5059-5068 Epub 2016 Aug 18. View ... 2016 Jun; 24 (6):2807-14 Epub 2016 Apr 04

  2. GS-4997 in Adults With Pulmonary Arterial Hypertension - Mayo Clinic

    The study will consist of a 24-week placebo-controlled treatment period and a long-term GS-4997 treatment period. Participants completing the 24-week ...

  3. A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma - Mayo Clinic

    ... 24 months) other than the disease being treated under study. The only allowed exceptions are: a) non-muscle invasive bladder cancer treated within the last 24 ...

  4. Oncology (Medical) - Clinical trials - Mayo Clinic

    Mayo Clinic Oncology — Medical oncologists at Mayo Clinic offer innovative treatments for cancers of the organs, bones, muscles and connective tissues.

  5. Publications - Cady K. Block, Ph.D., ABPP-CN, L.P. - Mayo Clinic

    2024 Oct 21; 1-24 [Epub ahead of print] View ... 2024 Jun; 155:109669 Epub 2024 Apr 24. View PubMed ... KA, Del Bene VA. Diverse experiences and ...

  6. Surgical Drain Fluid for Detection of Molecular Residual Disease for HPV(-) Head and Neck Cancers - Mayo Clinic

    ... 24- months post-surgery in patients with HPV(-) head and neck cancer. Participation eligibility. Participant eligibility includes age, gender, type and stage ...

  7. IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma - Mayo Clinic

    Rochester, Minnesota: 24-000858. NCT ID: NCT05987332. Sponsor Protocol Number: IDE196-002. About this study. The purpose of this study is to compare IDE196 + ...

  8. Clinical trials - Oncology (Medical)

    Rochester, Minn. This is a survey study to describe how women with Lynch syndrome are being screened for gynecologic cancer risk, their perception of cancer ...

  9. ... 24 hrs (6 yrs) 52 mg intrauterine device,959.24 392,636000003,50419042401,levonorgestreL 17.5 mcg/24 hrs (5yrs) 19.5mg intrauterine device,"1,907.02" 415 ...

  10. Publications - Tasneem Z. Naqvi, M.B.B.S., M.D. - Mayo Clinic

    Zeineddine RM, Naqvi TZ, Farina JM, Shawwaf KA, D'Cunha J, Jaroszewski DE. ... 2015 Dec; 210: (6)1118-24; discussion 1124-5. ... Epub 2012 Jan 24. View ...